Tag Archives: Federal Circuit

In a recent case, Pacific Biosciences of California, Inc. v. Oxford Nanopore Technologies, Inc., the Federal Circuit expanded the meaning of the enablement requirement under 35 U.S.C. § 112(a). Let’s take a look at how the court arrived at this decision.  The claims at issue were directed to methods for sequencing nucleic acid (DNA) using […]

In a recent case, Roche Molecular Systems, Inc. v. Cepheid, the Federal Circuit affirmed that claims directed to a nucleotide primer and claims directed to a detection method are invalid under 35 USC § 101. The patent covered primers and methods for a rapid detection of M. tuberculosis on the basis of the presence of […]